US4810424A - Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados - Google Patents
Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados Download PDFInfo
- Publication number
- US4810424A US4810424A US07/107,616 US10761687A US4810424A US 4810424 A US4810424 A US 4810424A US 10761687 A US10761687 A US 10761687A US 4810424 A US4810424 A US 4810424A
- Authority
- US
- United States
- Prior art keywords
- hepe
- periclados
- murrayella
- supply
- red alga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 16
- 241000142953 Murrayella periclados Species 0.000 title claims description 12
- BGNYXRDYZRBOGP-IBGZPJMESA-N (12s)-12-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCC[C@H](O)C=CC=CC=CC=CC=CC(O)=O BGNYXRDYZRBOGP-IBGZPJMESA-N 0.000 title description 2
- 238000011084 recovery Methods 0.000 title 1
- MCRJLMXYVFDXLS-UHFFFAOYSA-N 12-(S)-HEPE Natural products CCC=CCC=CCC(O)C=CC=CCC=CCCCC(O)=O MCRJLMXYVFDXLS-UHFFFAOYSA-N 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 8
- 150000004702 methyl esters Chemical class 0.000 claims description 4
- 230000001035 methylating effect Effects 0.000 claims 2
- 230000002879 macerating effect Effects 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 5
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000257465 Echinoidea Species 0.000 description 3
- 241000422392 Laurencia Species 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229940013317 fish oils Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000206640 Rhodomelaceae Species 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- -1 (11R)-hydroxy-5 Chemical class 0.000 description 1
- MCRJLMXYVFDXLS-UOLHMMFFSA-N 12(S)-HEPE Chemical compound CC\C=C/C\C=C/C[C@H](O)\C=C\C=C/C\C=C/CCCC(O)=O MCRJLMXYVFDXLS-UOLHMMFFSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 241000264277 Cystoseira barbata Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- MFBRTXIZJUHGPH-UHFFFAOYSA-N Hybridalactone Natural products OC1C(O)C(C(O)CO)OC1OCC1C(O)C(O)C(O)C(O)O1 MFBRTXIZJUHGPH-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000192710 Microcystis aeruginosa Species 0.000 description 1
- YJRNYEWLGNTSHT-UHFFFAOYSA-N N1-acetyl-N5,N10-di-(Z,E)-feruloylspermidine Natural products CCC1CC1C1C2CC3OC3C2C=CCC=CCCCC(=O)O1 YJRNYEWLGNTSHT-UHFFFAOYSA-N 0.000 description 1
- 241001663435 Ptilota filicina Species 0.000 description 1
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
- 241000258128 Strongylocentrotus purpuratus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- NSOPDUMLFDNMEX-AFJQJTPPSA-N ethyl (10Z,13Z)-hexadeca-10,13-dienoate Chemical compound CCOC(=O)CCCCCCCC\C=C/C\C=C/CC NSOPDUMLFDNMEX-AFJQJTPPSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 101150035983 str1 gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
Definitions
- This invention generally relates to the production of polyunsaturated fatty acids, and more specifically to the production of 12-(S)-hydroxyeicosapentaenoic acid.
- W-3 fats Polyunsaturated fatty acids possessing double bonds between the third and fourth carbon from the terminal methyl group (commonly known as W-3 fats) have been isolated in the tissues of fish. Tests conducted on these materials show considerable promise in the treatment of numerous diseases, including asthma, arteriosclerosis, heart disease, cancer, and various inflammatory conditions.
- W-3 fats While many of the W-3 fats are structurally similar to each other, each may affect the human body in a different way. This has created a demand for a wide variety of W-3 fats for research purposes.
- This article discusses the isolation from sea urchin eggs of a variety of compounds including (11R)-hydroxy-5,812,14-ZZEZ-eicosatetraenoic acid, (12R)-hydroxy-5,8,10,14-ZZEZ-eicosatetraenoic acid, and the (11R) and (12R)-hydroxy analogs of eicosapentaenoic acid.
- algal nonisoprenoids is presented in Moore, R. E., Marine Natural Products, Chemical and Biological Perspectives, Academic Press, Vol. 1, pp 42-124 (1978).
- This reference involves a review of important chemical materials obtainable from algae.
- the materials include those isolated from Aspargopsis taxiformis, an edible red alga from Hawaii. Almost 100 compounds have been isolated from this alga, as shown on pps. 61-63 of the reference.
- Also discussed on pps. 74-91 is the isolation of numerous lipid materials from a variety of forms of blue-green algae.
- 12-(S)-HEPE 12-(S)-hydroxy-5(Z),8(Z),10(E),14(Z), 17(Z)-eicosapentaenoic acid
- 12-(S)-HEPE 12-(S)-hydroxy-5(Z),8(Z),10(E),14(Z), 17(Z)-eicosapentaenoic acid
- radio-labeled 12-(S)-HEPE offers potential as an antibody-forming agent usable in radio amino assay kits designed to detect 12-(S)-HEPE in living tissue.
- radio-labeled 12-(S)-HEPE offers potential as an antibody-forming agent usable in radio amino assay kits designed to detect 12-(S)-HEPE in living tissue.
- radio amino assay kits designed to detect 12-(S)-HEPE in living tissue.
- EPA eicosapentaenoic acid
- 12-(S)-HEPE Since a practical and inexpensive method for obtaining this chemical did not exist prior to the present invention, 12-(S)-HEPE has traditionally been expensive and available only in limited amounts.
- the present ineention involves an inexpensive and simple method for producing substantial quantities of 12-(S)-HEPE. This method, as discussed in detail below, will make 12-(S)-HEPE more readily available to research scientists at a lower cost so that they may better understand its benefits in the treatment of disease.
- a method for producing 12-(S)-HEPE involves chemical extraction of the material from the red alga Murrayella periclados. Fresh or frozen quantities of Murrayella periclados are first macerated and combined with a 2:1 mixture of chloroform and methanol. This produces an organic solvent fraction containing lipid isolates from the Murrayella periclados. After filtration to remove extraneous solids, the organic fraction is evaporated to produce a tar. The tar contains 12-(S)-HEPE which is further purified to produce the final product.
- the present invention involves a novel procedure for producing substantial quantities of 12-(S)-HEPE at a low cost.
- the chemical structure of 12-(S)-HEPE is as follows: ##STR1## As previously discussed, this material is useful in the study of metabolism and is potentially valuable in the treatment of disease.
- Murrayella periclados in either fresh or fresh-frozen form is macerated (e.g. chopped and/or cut) and steeped for about 30 minutes in a chemical extractant, preferably consisting of a 2:1 mixture of chloroform and methanol.
- a chemical extractant preferably consisting of a 2:1 mixture of chloroform and methanol.
- the resulting liquid mixture is then passed through filter paper and allowed to cool.
- the mixture includes a discrete organic phase which contains lipid materials from the Murrayella periclados. This phase is separated from the aqueous phase of the mixture using a separatory funnel.
- the organic phase is then evaporated under reduced pressure.
- the resulting product consists of an organic tar containing the 12-(S)-HEPE.
- a typical yield of tar is 8.0 grams of tar per 363 grams (dry weight) of extracted Murrayella periclados.
- the organic tar is then added to about 350 cc of thin layer chromatography grade silica gel in a vacuum funnel measuring 9.5 cm I.D. by 8.5 cm in height.
- the tar is progressively eluted with increasingly polar mixtures of ethyl acetate in isooctane.
- the eluted materials resulting from the addition of 1% to 40% ethyl acetate in isooctane are discarded.
- the eluted materials obtained from the introduction of 50-100% ethyl acetate in isooctane are retained. The retained materials are evaporated to remove the solvent, and the resulting product is applied to a thick layer chromatography plate (Kieselgel 60 F 254 , 2 mm thick).
- the qualitative identification of the 12-(S)-HEPE can be made by a thin layer chromatographic comparison with standardized quantities of the material, or by conventional spectroscopic and analytical methods (nuclear magnetic resonance spectroscopy or mass spectrometry).
- the product may be purified as a derivative which involves methylation of the 12-(S)-HEPE to the corresponding methyl ester using diazomethane followed by vacuum silica gel chromatography and elution with 10-20% ethyl acetate in isooctane.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/107,616 US4810424A (en) | 1987-10-09 | 1987-10-09 | Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/107,616 US4810424A (en) | 1987-10-09 | 1987-10-09 | Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados |
Publications (1)
Publication Number | Publication Date |
---|---|
US4810424A true US4810424A (en) | 1989-03-07 |
Family
ID=22317506
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US07/107,616 Expired - Fee Related US4810424A (en) | 1987-10-09 | 1987-10-09 | Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados |
Country Status (1)
Country | Link |
---|---|
US (1) | US4810424A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6447782B1 (en) * | 1998-09-09 | 2002-09-10 | Parfums Christian Dior | Lipid extract of the Skeletonema algae |
WO2001060778A3 (en) * | 2000-02-16 | 2003-01-16 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
US20040116408A1 (en) * | 2002-08-12 | 2004-06-17 | Serhan Charles N. | Resolvins: biotemplates for novel therapeutic interventions |
US20050238589A1 (en) * | 2004-04-14 | 2005-10-27 | Van Dyke Thomas E | Methods and compositions for preventing or treating periodontal diseases |
US20060024758A1 (en) * | 2003-03-05 | 2006-02-02 | Serhan Charles N | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
US7030159B2 (en) | 2001-12-18 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs |
US20080096961A1 (en) * | 2002-08-12 | 2008-04-24 | The Brigham And Women's Hospital, Inc. | Use of Docosatrienes, Resolvins and Their Stable Analogs in the Treatment of Airway Diseases and Asthma |
US20080280980A1 (en) * | 2005-11-18 | 2008-11-13 | Trustees Of Boston Univeristy | Treatment and Prevention of Bone Loss Using Resolvins |
US20090156673A1 (en) * | 2005-10-03 | 2009-06-18 | The Brigham And Women's Hospital, Inc. Corporate Sponsored Research & Licensing | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and it's natural stereoisomers |
US7902257B2 (en) | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
US8481772B2 (en) | 2002-04-01 | 2013-07-09 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
-
1987
- 1987-10-09 US US07/107,616 patent/US4810424A/en not_active Expired - Fee Related
Non-Patent Citations (42)
Title |
---|
Aponte, N. E., "The Life History and Development of Murrayella Periclados (C. Agardh) Schmitz (Rhodophyta, Rhodomelaceae) in Culture," Crytogamie, Algologie 8(1): 29-39 (1987). |
Aponte, N. E., The Life History and Development of Murrayella Periclados (C. Agardh) Schmitz (Rhodophyta, Rhodomelaceae) in Culture, Crytogamie, Algologie 8(1): 29 39 (1987). * |
Biomol Catalog Listing for 1986 87, The Source . * |
Biomol Catalog Listing for 1986-87, "The Source". |
Boukhchache, D. et al., "Interactions Between Prostaglandin Precursors During Their Oxygenation by Human Platelets," Biochemica et Biophysica Acta, 713: 386-392 (1982). |
Boukhchache, D. et al., Interactions Between Prostaglandin Precursors During Their Oxygenation by Human Platelets, Biochemica et Biophysica Acta, 713: 386 392 (1982). * |
Croset, M. et al., "Stereospecific Inhibition of PGH2 -Induced Platelet Aggregation by Lipoxygenase Products of Icosaenoic Acids", Biochemical and Biophysical Research Communications, 112 (3): 878-883 (1983). |
Croset, M. et al., Stereospecific Inhibition of PGH 2 Induced Platelet Aggregation by Lipoxygenase Products of Icosaenoic Acids , Biochemical and Biophysical Research Communications, 112 (3): 878 883 (1983). * |
Cunningham, F. M. et al., "Proinflammatory Properties of Unsaturated Fatty Acids and Their Monohydroxy Metabolites," Prostaglandins, 30 (3): 497-509 (1985). |
Cunningham, F. M. et al., Proinflammatory Properties of Unsaturated Fatty Acids and Their Monohydroxy Metabolites, Prostaglandins, 30 (3): 497 509 (1985). * |
Gunstone, F. O., "Fatty Acids and Glycerides", Natural Product Reports, 95-113 (1987). |
Gunstone, F. O., Fatty Acids and Glycerides , Natural Product Reports, 95 113 (1987). * |
Hamberg, M., "Transformations of 5,8,11,14,17-Eicosapentaenoic Acid in Human Platelets", Biochemica et Biophysica Acta, 618: 389-398 (1980). |
Hamberg, M., Transformations of 5,8,11,14,17 Eicosapentaenoic Acid in Human Platelets , Biochemica et Biophysica Acta, 618: 389 398 (1980). * |
Hashimoto, Y. et al., "Effects of Arachidonic Acid on the Metabolism of Eicosapentaenoic Acid in Washed Human Platelets," Thrombosis Research, 40: 307-317 (1985). |
Hashimoto, Y. et al., Effects of Arachidonic Acid on the Metabolism of Eicosapentaenoic Acid in Washed Human Platelets, Thrombosis Research, 40: 307 317 (1985). * |
Hawkins, D. J. & Brash, A. R., "Eggs of the Sea Urchin, Strongylocentrotus purpuratus, Contain a Prominent (11R) and (12R) Lipoxygenase Activity", The Journal of Biological Chemistry, vol. 262, 7629-7634 (1987). |
Hawkins, D. J. & Brash, A. R., Eggs of the Sea Urchin, Strongylocentrotus purpuratus, Contain a Prominent (11R) and (12R) Lipoxygenase Activity , The Journal of Biological Chemistry, vol. 262, 7629 7634 (1987). * |
Higgs, M. D., "Antimicrobial Components of the Red Alga Laurencia Hybrida (Rhodophyta, Rhodomelaceae)", Tetrahedron, vol. 37, 4255-4258 (1981). |
Higgs, M. D., "Hybridalactone, An Unusual Fatty Acid Metabolite from the Red Alga Laurencia Hybrida (Rhodophyta, Rhodomelaceae)", Tetrahedron, vol. 37, 4259-4262 (1981). |
Higgs, M. D., Antimicrobial Components of the Red Alga Laurencia Hybrida (Rhodophyta, Rhodomelaceae) , Tetrahedron, vol. 37, 4255 4258 (1981). * |
Higgs, M. D., Hybridalactone, An Unusual Fatty Acid Metabolite from the Red Alga Laurencia Hybrida (Rhodophyta, Rhodomelaceae) , Tetrahedron, vol. 37, 4259 4262 (1981). * |
Kulkarni, P. S. et al., "Eicosapentaenoic Acid Metabolism in Human and Rabbit Anterior Uvea," Prostaglandins, 31(6): 1159-1164 (1986). |
Kulkarni, P. S. et al., Eicosapentaenoic Acid Metabolism in Human and Rabbit Anterior Uvea, Prostaglandins, 31(6): 1159 1164 (1986). * |
Lagarde, M. et al., "Lipoxygenase Activity of Intact Human Platelets," Prostaglandins Leukotrienes and Medicine, 13: 61-66 (1984). |
Lagarde, M. et al., "Role of Lipoxygenase Products in Platelet Function: Relation to Fatty Acid Modified Phospholipids," pp. 327-335. |
Lagarde, M. et al., Lipoxygenase Activity of Intact Human Platelets, Prostaglandins Leukotrienes and Medicine, 13: 61 66 (1984). * |
Lagarde, M. et al., Role of Lipoxygenase Products in Platelet Function: Relation to Fatty Acid Modified Phospholipids, pp. 327 335. * |
Lopez, A. & Gerwick, W. H., Lipids, vol. 22, 190 194 (1987). * |
Lopez, A. & Gerwick, W. H., Lipids, vol. 22, 190-194 (1987). |
Lopez, A. et al., "Two New Icosapentaenoic Acids from the Temperate Red Seaweed Ptilota filicina J. Agardh," Lipids, 22 (3): 190-194 (1987). |
Lopez, A. et al., Two New Icosapentaenoic Acids from the Temperate Red Seaweed Ptilota filicina J. Agardh, Lipids, 22 (3): 190 194 (1987). * |
Moore, R. E., Marine Natural Products, Chemical and Biological Perspectives, Academic Press, vol. 1, pp. 42 124 (1978). * |
Moore, R. E., Marine Natural Products, Chemical and Biological Perspectives, Academic Press, vol. 1, pp. 42-124 (1978). |
Pace Asciak, C. R., Formation of Hepoxilin A4, B4 and the Corresponding Trioxilins from 12(S) Hydroperoxy 5,8,10,14,17 Icosapentaenoic Acid, Prostaglandins Leukotrienes and Medicine, 22: 1 9 (1986). * |
Pace-Asciak, C. R., "Formation of Hepoxilin A4, B4 and the Corresponding Trioxilins from 12(S)-Hydroperoxy-5,8,10,14,17-Icosapentaenoic Acid," Prostaglandins Leukotrienes and Medicine, 22: 1-9 (1986). |
Powell, W. S. et al., "Metabolism of Eicosapentaenoic Acid by Aorta: Formation of a Novel 13-Hydroxylated Prostaglandin", Biochemica et Biophysica Acta, 835: 201-211 (1985). |
Powell, W. S. et al., Metabolism of Eicosapentaenoic Acid by Aorta: Formation of a Novel 13 Hydroxylated Prostaglandin , Biochemica et Biophysica Acta, 835: 201 211 (1985). * |
Takenaga, M. et al., "Comparison of the In Vitro Effect of Eicosapentaenoic Acid (EPA)-Derived Lipoxygenase Metabolites on Human Platelet Function with Those of Arachidonic Acid," Thrombosis Research, 37: 373-384 (1986). |
Takenaga, M. et al., Comparison of the In Vitro Effect of Eicosapentaenoic Acid (EPA) Derived Lipoxygenase Metabolites on Human Platelet Function with Those of Arachidonic Acid, Thrombosis Research, 37: 373 384 (1986). * |
Taylor, W. R., "Marine Algae of the Eastern Tropical and Subtropical Coasts of the Americas", The University of Michigan Press, (1960). |
Taylor, W. R., Marine Algae of the Eastern Tropical and Subtropical Coasts of the Americas , The University of Michigan Press, (1960). * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6447782B1 (en) * | 1998-09-09 | 2002-09-10 | Parfums Christian Dior | Lipid extract of the Skeletonema algae |
US20070049639A1 (en) * | 2000-02-16 | 2007-03-01 | Serhan Charles N | Aspirin-triggered lipid mediators |
US7709669B2 (en) | 2000-02-16 | 2010-05-04 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
US7737178B2 (en) | 2000-02-16 | 2010-06-15 | The Brigham And Woman's Hospital, Inc. | Aspirin-triggered lipid mediators |
US20040059144A1 (en) * | 2000-02-16 | 2004-03-25 | Serhan Charles N. | Aspirin-triggered lipid mediators |
US8349896B2 (en) | 2000-02-16 | 2013-01-08 | The Brigham And Womens's Hospital, Inc. | Aspirin-triggered lipid mediators |
US7053230B2 (en) | 2000-02-16 | 2006-05-30 | Serhan Charles N | Aspirin-triggered lipid mediators |
WO2001060778A3 (en) * | 2000-02-16 | 2003-01-16 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
US7741368B2 (en) | 2001-12-18 | 2010-06-22 | The Brigham And Women's Hospital, Inc. | Approach to antimicrobial host defense with molecular shields with EPA and DHA analogs |
US7030159B2 (en) | 2001-12-18 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Approach to anti-microbial host defense with molecular shields with EPA and DHA analogs |
US8461201B2 (en) | 2002-04-01 | 2013-06-11 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US7902257B2 (en) | 2002-04-01 | 2011-03-08 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid |
US20110237545A1 (en) * | 2002-04-01 | 2011-09-29 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US8481772B2 (en) | 2002-04-01 | 2013-07-09 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US8802874B2 (en) | 2002-04-01 | 2014-08-12 | University Of Southern California | Trihydroxy polyunsaturated eicosanoid derivatives |
US20100016432A1 (en) * | 2002-08-12 | 2010-01-21 | The Brigham And Women's Hospital, Inc. | Resolvins: biotemplates for novel therapeutic interventions |
JP2005535712A (en) * | 2002-08-12 | 2005-11-24 | ブライハム アンド ウイメンズ ホスピタル | Resolvin: Biotemplate for therapeutic treatment |
US8933270B2 (en) | 2002-08-12 | 2015-01-13 | The Brigham And Women's Hospital, Inc. | Use of docasatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma |
US20040116408A1 (en) * | 2002-08-12 | 2004-06-17 | Serhan Charles N. | Resolvins: biotemplates for novel therapeutic interventions |
US8569542B2 (en) | 2002-08-12 | 2013-10-29 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma |
US7585856B2 (en) | 2002-08-12 | 2009-09-08 | The Brigham And Women's Hospital, Inc. | Resolvins: Biotemplates for novel therapeutic interventions |
US7872152B2 (en) | 2002-08-12 | 2011-01-18 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
US20080096961A1 (en) * | 2002-08-12 | 2008-04-24 | The Brigham And Women's Hospital, Inc. | Use of Docosatrienes, Resolvins and Their Stable Analogs in the Treatment of Airway Diseases and Asthma |
US7803557B2 (en) | 2003-03-05 | 2010-09-28 | The Brigham And Women's Hospital, Inc. | Methods for identification of eicosapentaenoic acid analogs using anti-inflammatory receptors |
US20060024758A1 (en) * | 2003-03-05 | 2006-02-02 | Serhan Charles N | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
US7341840B2 (en) | 2003-03-05 | 2008-03-11 | The Brigham And Women's Hospital, Inc. | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
US20090180961A1 (en) * | 2003-03-05 | 2009-07-16 | Serhan Charles N | Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs |
US20050238589A1 (en) * | 2004-04-14 | 2005-10-27 | Van Dyke Thomas E | Methods and compositions for preventing or treating periodontal diseases |
US8273792B2 (en) | 2005-10-03 | 2012-09-25 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers |
US20090156673A1 (en) * | 2005-10-03 | 2009-06-18 | The Brigham And Women's Hospital, Inc. Corporate Sponsored Research & Licensing | Anti-inflammatory actions of neuroprotectin d1/protectin d1 and it's natural stereoisomers |
US9364454B2 (en) | 2005-10-03 | 2016-06-14 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers |
US20080280980A1 (en) * | 2005-11-18 | 2008-11-13 | Trustees Of Boston Univeristy | Treatment and Prevention of Bone Loss Using Resolvins |
US8636986B2 (en) | 2005-11-18 | 2014-01-28 | The Forsyth Institute | Treatment and prevention of bone loss using resolvins |
US9968577B2 (en) | 2005-11-18 | 2018-05-15 | Forsyth Dental Infirmary For Children | Treatment and prevention of bone loss using resolvins |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Loeblich III et al. | Chloroplast pigments of the marine dinoflagellate Gyrodinium resplendens | |
Wertz et al. | Integral lipids of human hair | |
da Graça Sgarbi et al. | Isolation of ergosterol peroxide and its reversion to ergosterol in the pathogenic fungus Sporothrix schenckii | |
EP0862547B1 (en) | Products extracted from a plant of the genus commiphora, particularly the commiphora mukul plant, extracts containing same and applications thereof, for example in cosmetics | |
US4810424A (en) | Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados | |
D'Costa et al. | Changes in the lipid content during the metamorphosis of the blowfly, Lucilia | |
Barbosa et al. | Investigation-Research: Chemical constituents from Mucuna aterrima with activity against Meloidogyne incognita and Heterodera glycines | |
EP0012246A1 (en) | Aromatic and flavouring substances, their preparation by fermentation, their use and products containing them | |
DE68902670T2 (en) | KS-506 CONNECTIONS AND METHOD FOR THE PRODUCTION THEREOF. | |
US4046914A (en) | Therapeutically active substituted saturated and mono-and polyunsaturated alkyl-glycerylethers | |
Gerwick et al. | Eicosanoids from the Rhodophyta: new metabolism in the algae | |
US5077202A (en) | Process for producing a glycolipid having a high eicosapentaenoic acid content | |
FR2543144A1 (en) | PROCESS FOR ISOLATING SOYBEAN SAPONINS | |
Brooks et al. | Tumour-promoting and hyperplastic effects of phorbol and daphnane esters in CD-1 mouse skin and a synergistic effect of calcium ionophore with the non-promoting activator of protein kinase C, sapintoxin A | |
Hitcho et al. | Possible molting and maturation controls in Trichinella spiralis | |
JPH02247125A (en) | Inhibitor of malignant tumor cell multiplication | |
Ramesh et al. | Selective extraction of phospholipids from egg yolk | |
US6384085B1 (en) | Material separated from Ecklonia cava, method for extracting and purifying the same, and use thereof as antioxidants | |
Mancini et al. | Novel 10‐Hydroxydocosapolyenoic Acids from Deep‐Water Scleractinian Corals | |
Bollinger | The isolation and tentative identification of diacylglyceryl ethers from the walker 256 carcinoma of the rat and a human lymphosarcoma | |
AKIHISA et al. | Widespread occurrence of cucurbita-5, 24-dienol in Cucurbitaceae | |
US6774145B1 (en) | Material separated from Ecklonia cava, method for extracting and purifying the same, and use thereof as antioxidants | |
JPS58201736A (en) | Polyprenol manufacturing method | |
BAUMANN et al. | Alk-1-enyl ethers of glycerol and ethanediol | |
US3713980A (en) | Process for the preparation of peruvoside |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STATE OF OREGON ACTING BY AND THROUGH THE OREGON S Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:GERWICK, WILLIAM H.;REEL/FRAME:004787/0831 Effective date: 19871103 Owner name: STATE OF OREGON ACTING BY AND THROUGH THE OREGON S Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GERWICK, WILLIAM H.;REEL/FRAME:004787/0831 Effective date: 19871103 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19930307 |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |